Myfanwy Graham
YOU?
Author Swipe
View article: Understanding medical cannabis use internationally: Why definitions and context matter
Understanding medical cannabis use internationally: Why definitions and context matter Open
Aims To identify variation in identification of medical consumers using alternative self‐reported measures and assess whether differences in these rates exist across jurisdictions with different medical policy approaches using evidence fro…
View article: The safety and efficacy of cannabinoids for the treatment of mental health and substance use disorders: protocol for a systematic review and meta-analysis
The safety and efficacy of cannabinoids for the treatment of mental health and substance use disorders: protocol for a systematic review and meta-analysis Open
There has been a global increase in the use of cannabinoids as a treatment for mental health (MH) and substance use disorders (SUD). In 2016, an Australian government-funded review found that although medicinal cannabinoids accounted for a…
View article: <scp>NSW</scp> cannabis medicines advisory service retrospective enquiry analysis to inform clinical guidance resource development
<span>NSW</span> cannabis medicines advisory service retrospective enquiry analysis to inform clinical guidance resource development Open
Background An innovative New South Wales government funded statewide Cannabis Medicines Advisory Service (CMAS) operated between January 2018 and June 2022. The service provided comprehensive patient‐specific and evidence‐based information…
View article: ‘The wild west of medicine’: A qualitative investigation of the factors influencing Australian health‐care practitioners' delivery of medicinal cannabis
‘The wild west of medicine’: A qualitative investigation of the factors influencing Australian health‐care practitioners' delivery of medicinal cannabis Open
Introduction Strong patient interest in the use of medicinal cannabis to treat various clinical indications has sparked global legislative changes. Practitioners are vital in implementing regulatory changes and facilitating patient access …
View article: The safety and efficacy of cannabinoids for the treatment of mental health and substance use disorders: protocol for a systematic review and meta-analysis
The safety and efficacy of cannabinoids for the treatment of mental health and substance use disorders: protocol for a systematic review and meta-analysis Open
There has been a global increase in the use of cannabinoids as a treatment for mental health (MH) and substance use disorders (SUD). In 2016, an Australian government-funded review found that although medicinal cannabinoids accounted for a…
View article: A provisional evaluation of Australia's medical cannabis program
A provisional evaluation of Australia's medical cannabis program Open
In 2016, the Australian Government legislated to allow cannabis to be prescribed to patients as an unapproved medicine under the special access provisions of the Therapeutic Goods Act. This paper compares the Australian regulatory approach…
View article: Table of Contents
Table of Contents Open
View article: From growers to patients: Multi-stakeholder views on the use of, and access to medicinal cannabis in Australia
From growers to patients: Multi-stakeholder views on the use of, and access to medicinal cannabis in Australia Open
Background Patient interest in the use of cannabis-based medicines (CBMs) has increased in Australia. While recent policy and legislative changes have enabled health practitioners to prescribe CBMs for their patients, many patients still s…
View article: Cannabinoids - Recent Perspectives and Applications in Human Health
Cannabinoids - Recent Perspectives and Applications in Human Health Open
Cannabinoids - Recent Perspectives and Applications in Human Health presents the latest research on cannabinoids for human health, covering topics such as potential emerging therapeutic applications and safety concerns. Not only doe…
View article: Cannabis Medicines: Guidance for the Selection, Purchase and Supply for Clinical Trials
Cannabis Medicines: Guidance for the Selection, Purchase and Supply for Clinical Trials Open
Cannabis medicines are in demand from the public for treating a range of diseases and symptoms; however, clinicians are reluctant to prescribe these products because of limited evidence and prescribing information. To generate this evidenc…
View article: Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies
Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies Open
View article: Expert advice for prescribing cannabis medicines for patients with epilepsy—drawn from the Australian clinical experience
Expert advice for prescribing cannabis medicines for patients with epilepsy—drawn from the Australian clinical experience Open
There is international interest for consensus advice for prescribers working in the field of drug resistant epilepsy intending to trial potential therapies that are nonregistered or off‐label. Cannabinoids are one such therapy. In 2017, th…
View article: Medicinal cannabis prescribing guidance documents: An evidence-based, best-practice framework based on the New South Wales experience
Medicinal cannabis prescribing guidance documents: An evidence-based, best-practice framework based on the New South Wales experience Open
Introduction: In 2018, the Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE), a National Health and Medical Research Council (NHMRC) Centre of Research Excellence was funded to develop a suite of state-wide medicina…
View article: <scp>NSW</scp> Cannabis Medicines Advisory Service preliminary survey results: enquirer perceptions and patient outcomes
<span>NSW</span> Cannabis Medicines Advisory Service preliminary survey results: enquirer perceptions and patient outcomes Open
Background In 2018, an innovative, State government‐funded cannabis medicines drug information service was established for health professionals in New South Wales (NSW). The NSW Cannabis Medicines Advisory Service (CMAS) provides expert cl…
View article: Anti-Oxidant Phytochemicals as Potential Treatments for Age-Related Macular Degeneration
Anti-Oxidant Phytochemicals as Potential Treatments for Age-Related Macular Degeneration Open
Age-related macular degeneration (AMD) is responsible for a substantial proportion of severe visual impairment and blindness in people over 50 years of age. Current treatments for AMD are not effective in all patients and a proportion of p…